Pulnovo Medical Names Dr. Francis Duhay as Global CMO

August 25, 2025—Pulnovo Medical, a developer of mechanism-driven therapies for pulmonary hypertension and heart failure, announced the appointment of Francis Duhay, MD, as Global Chief Medical Officer. Dr. Duhay is a board-certified general and cardiothoracic surgeon with more than 25 years of experience in clinical medicine, medical device innovation, and executive leadership.

The company advised that Dr. Duhay’s appointment strengthens its global medical leadership as it advances its pulmonary artery denervation (PADN) program and expands its footprint in international markets.

The press release noted that Dr. Duhay previously served as Chief Medical Officer at Edwards Lifesciences, where he played a decisive role in the development, clinical validation, and worldwide adoption of transcatheter aortic valve replacement. Additionally, his career spans leadership of 88 clinical studies across multiple specialties and close collaboration with global regulatory bodies, including the FDA and the Centers for Medicare & Medicaid Services, stated Pulnovo.

In April 2025, Pulnovo announced that its PADN catheter for treating pulmonary hypertension received CE Mark clearance under the European Union Medical Device Regulation. The device is also approved in China. In the United States, it received approval for a humanitarian use device exemption, as well as a Category III CPT code.